老年2型糖尿病并发症的治疗新进展

doi:10.3969/j.issn.1003-9198.2022.10.005

摘要/Abstract

中图分类号:

R587.1

李盖, 王雷, 孙新娟, 王天元, 陈金安. 老年2型糖尿病并发症的治疗新进展[J]. 实用老年医学, 2022, 36(10): 991-995.

[1] SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 [J]. Diabetes Res Clin Pract, 2022, 183: 109119.
[2] HOLMAN N, YOUNG B, GADSBY R. Current prevalence of type 1 and type 2 diabetes in adults and children in the UK [J]. Diabet Med, 2015, 32(9): 1119-1120.
[3] 中国老年2型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中华内科杂志, 2022, 61(1): 12-50.
[4] DA ROCHA FERNANDES J, OGURTSOVA K, LINNENKAMP U, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes [J]. Diabetes Res Clin Pract, 2016, 117: 48-54.
[5] SCHELLENBERG E S, DRYDEN D M, VANDERMEER B, et al. Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis [J]. Ann Intern Med, 2013, 159(8): 543-551.
[6] BOOTH G L, KAPRAL M K, FUNG K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study [J]. Lancet, 2006, 368(9529): 29-36.
[7] BECKMAN J A, PANENI F, COSENTINO F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II [J]. Eur Heart J, 2013, 34(31): 2444-2452.
[8] PARRY H M, DESHMUKH H, LEVIN D, et al. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus [J]. Circ Heart Fail, 2015, 8(2): 236-242.
[9] CHEN A, WANG H, SU Y, et al. Exosomes: biomarkers and therapeutic targets of diabetic vascular complications [J]. Front Endocrinol: Lausanne, 2021, 12: 720466.
[10] SUN Y, SHI H, YIN S, et al. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving beta-cell destruction [J]. ACS Nano, 2018, 12(8): 7613-7628.
[11] MULLER-WIELAND D, KELLERER M, CYPRYK K, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes [J]. Diabetes Obes Metab, 2018, 20(11): 2598-2607.
[12] GROUP A S C, BOWMAN L, MAFHAM M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus [J]. N Engl J Med, 2018, 379(16): 1529-1539.
[13] 孙敏, 张冬颖. 钠-葡萄糖共转运蛋白2抑制剂对2型糖尿病患者心血管保护作用的研究进展 [J]. 上海交通大学学报(医学版), 2021, 41(3): 391-395.
[14] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)(下) [J]. 中国实用内科杂志, 2021, 41(9): 757-784.
[15] 王富军. 中国糖尿病足防治指南(2019版)解读 [J]. 河北医科大学学报, 2019, 40(11): 1241-1250.
[16] PANENI F, BECKMAN J A, CREAGER M A, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I [J]. Eur Heart J, 2013, 34(31): 2436-2443.
[17] SELVIN E, CORESH J, BRANCATI F L. The burden and treatment of diabetes in elderly individuals in the U.S [J]. Diabetes Care, 2006, 29(11): 2415-2419.
[18] MARTINEZ-CASTELAO A, NAVARRO-GONZALEZ J F, GORRIZ J L, et al. The concept and the epidemiology of diabetic nephropathy have changed in recent years [J]. J Clin Med, 2015, 4(6): 1207-1216.
[19] VAN DIEREN S, BEULENS J W, VAN DER SCHOUW Y T, et al. The global burden of diabetes and its complications: an emerging pandemic [J]. Eur J Cardiovasc Prev Rehabil, 2010, 17(Suppl 1): S3-S8.
[20] DONATE-CORREA J, LUIS-RODRÍGUEZ D, MARTÍN-NÚÑEZ E, et al. Inflammatory targets in diabetic nephropathy [J]. J Clin Med, 2020, 9(2):458.
[21] PUGLIESE G, PENNO G, NATALI A, et al. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function" [J]. J Nephrol, 2020, 33(1): 9-35.
[22] KIM M K. Treatment of diabetic kidney disease: current and future targets [J]. Korean J Intern Med, 2017, 32(4): 622-630.
[23] DAVID F, SILVIO E, CHRISTOPHER P, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial[J]. Circulation, 2019, 139(11):1384-1395.
[24] ZOUNGAS S, CHALMERS J, NINOMIYA T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds [J]. Diabetologia, 2012, 55(3): 636-643.
[25] ROETT M A, LIEGL S, JABBARPOUR Y. Diabetic nephropathy-the family physician's role [J]. Am Fam Physician, 2012, 85(9): 883-889.
[26] UMANATH K, LEWIS J B. Update on diabetic nephropathy: core curriculum 2018 [J]. Am J Kidney Dis, 2018, 71(6): 884-895.
[27] ARORA M K, SINGH U K. Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update [J]. Vascul Pharmacol, 2013, 58(4): 259-271.
[28] SAKLAYEN M G, GYEBI L K, TASOSA J, et al. Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial [J]. J Investig Med, 2008, 56(4): 714-719.
[29] GUILLAUME J, JEAN C, CHARLES C.Vitamin D in chronic kidney disease and dialysis patients[J]. Nutrients, 2017, 9(4):328.
[30] DE ZEEUW D, RENFURM R W, BAKRIS G, et al. Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial [J]. Lancet Diabetes Endocrinol, 2018, 6(12): 925-933.
[31] KLEIN R, KLEIN B E, MOSS S E. Visual impairment in diabetes [J]. Ophthalmology, 1984, 91(1): 1-9.
[32] 阚芳芳, 方福生, 孙般诺, 等. 不同发病年龄老年2型糖尿病的临床特点[J]. 中华保健医学杂志, 2015, 17(5): 360-363.
[33] 高晔, 孙桂波, 罗云, 等. 糖尿病视网膜病的发病机制及药物干预研究进展[J]. 中国药理学通报, 2020, 36(4): 491-495.
[34] KITADA M, KUME S, IMAIZUMI N, et al. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway[J]. Diabetes, 2011, 60(2): 634-643.
[35] LIU K, WANG H, HE W, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study [J]. Br J Ophthalmol, 2021. DOI: 10.1136/BJOPHTHALMOL-2020-318690.
[36] POP-BUSUI R, BOULTON A J, FELDMAN E L, et al. Diabetic neuropathy: a position statement by the American Diabetes Association [J]. Diabetes Care, 2017, 40(1): 136-154.
[37] TESFAYE S, STEVENS L K, STEPHENSON J M, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study [J]. Diabetologia, 1996, 39(11): 1377-1384.
[38] TESFAYE S, CHATURVEDI N, EATON S E, et al. Vascular risk factors and diabetic neuropathy [J]. N Engl J Med, 2005, 352(4): 341-350.
[39] CALLAGHAN B C, CHENG H T, STABLES C L, et al. Diabetic neuropathy: clinical manifestations and current treatments [J]. Lancet Neurol, 2012, 11(6): 521-534.
[40] TESFAYE S, VILEIKYTE L, RAYMAN G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management [J]. Diabetes Metab Res Rev, 2011, 27(7): 629-638.
[41] JAVED S, PETROPOULOS I N, ALAM U, et al. Treatment of painful diabetic neuropathy [J]. Ther Adv Chronic Dis, 2015, 6(1): 15-28.
[42] CHANG M, NGUYEN T T. Strategy for treatment of infected diabetic foot ulcers [J]. Acc Chem Res, 2021, 54(5): 1080-1093.
[43] 中华医学会糖尿病学分会神经并发症学组. 糖尿病神经病变诊治专家共识(2021年版) [J]. 国际内分泌代谢杂志, 2021, 41(3): 256-272.
[44] BOULTON A J M. The diabetic foot [J]. Medicine, 2019, 47(2): 100-105.
[45] BEYAZ S, GULER U O, BAGIR G S. Factors affecting lifespan following below-knee amputation in diabetic patients [J]. Acta Orthop Traumatol Turc, 2017, 51(5): 393-397.
[46] JIANG Y, RAN X, JIA L, et al. Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China [J]. Int J Low Extrem Wounds, 2015, 14(1): 19-27.
[47] EIKELBOOM J W, CONNOLLY S J, BOSCH J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease [J]. N Engl J Med, 2017, 377(14): 1319-1330.
[48] OKAMOTO S, IIDA O, TAKAHARA M, et al. Impact of perioperative complications after endovascular therapy in diabetic patients with critical limb ischemia due to isolated infrapopliteal lesions [J]. J Endovasc Ther, 2016, 23(2): 371-377.
[49] 《多学科合作下糖尿病足防治专家共识》编写组. 多学科合作下糖尿病足防治专家共识(2020版)精华版(Ⅰ) [J]. 中华烧伤杂志, 2020, 36(8): 637-646.
[50] FRYKBERG R G, WUKICH D K, KAVARTHAPU V, et al. Surgery for the diabetic foot: a key component of care [J]. Diabetes Metab Res Rev, 2020, 36 (Suppl 1): e3251.

老年2型糖尿病并发症的治疗新进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

推荐阅读 10

[1]	张星星, 张海洋, 何小菁, 鲁翔. 不同肥胖指标与老年人糖尿病患病风险的调查研究[J]. 实用老年医学, 2024, 38(9): 940-943.
[2]	赵玉玲, 黄婧, 叶文春. 血清γ-氨基丁酸、胰岛素样生长因子-1对老年糖尿病前期病人心血管事件风险的交互作用分析[J]. 实用老年医学, 2024, 38(8): 816-820.
[3]	梁杉杉, 梁欢, 杨珊, 刘建凤. 老年T2DM病人肌少症发生与颈动脉粥样硬化的相关性研究[J]. 实用老年医学, 2024, 38(8): 826-830.
[4]	时雯, 朱平, 周洁, 颜婷, 黄玉杰, 严妍. 胰激肽原酶治疗老年2型糖尿病轻度认知功能障碍的疗效观察[J]. 实用老年医学, 2024, 38(6): 587-591.
[5]	郭淳, 易梦廷, 宗前兴, 周怡, 巫海娣, 莫永珍. 老年2型糖尿病病人6个月内低血糖风险预测模型的构建:一项纵向研究[J]. 实用老年医学, 2024, 38(6): 592-597.
[6]	包海童, 谈萍, 俞沛文, 刘娟, 丁国宪, 佟蔷薇, 王晓东. 基于老年综合评估的2型糖尿病病人衰弱影响因素分析[J]. 实用老年医学, 2022, 36(12): 1264-1268.
[7]	陈明珠, 许勤, 蔡英华. 老年糖尿病合并衰弱病人自我感受负担的现状及影响因素分析[J]. 实用老年医学, 2022, 36(12): 1269-1272.
[8]	祖丽胡玛尔·阿布都艾尼, 刘超. 老年糖尿病的流行病学特点[J]. 实用老年医学, 2022, 36(10): 973-977.
[9]	唐伟, 张子成. 老年糖尿病血糖监测技术新进展[J]. 实用老年医学, 2022, 36(10): 978-982.
[10]	徐千越, 胡云. 注射类降糖药物在老年糖尿病病人中的使用新进展[J]. 实用老年医学, 2022, 36(10): 983-985.
[11]	叶德梅, 张俊, 殷汉, 李玲. 老年糖尿病口服降糖药物新进展[J]. 实用老年医学, 2022, 36(10): 986-990.
[12]	俞匀, 唐伟, 娄青林. 不同发病年龄新诊断2型糖尿病病人临床特点分析[J]. 实用老年医学, 2022, 36(10): 1015-1018.
[13]	姚铸玲, 王志勇, 熊亚晴, 徐斐. 南京市老年人群高血压合并糖尿病的流行特征[J]. 实用老年医学, 2022, 36(8): 796-800.
[14]	包宇航, 郑仁东. 糖代谢与睾酮关系的研究进展[J]. 实用老年医学, 2022, 36(8): 850-853.
[15]	仰孝群, 欧阳晓俊. 糖尿病与衰弱相关研究进展[J]. 实用老年医学, 2022, 36(7): 655-659.